Senators and House members expressed their strong objections to the DEA’s interim final rule in two recent letters to the DEA’s acting administrator.
Category: Other Cannabinoids
HIA and RE Botanicals filed a second legal action against the DEA regarding the Interim Final Rule (IFR). Kight Law is proud to be part of the legal team.
On Friday, October 2, 2020, I will be discussing hemp business law along with my colleague, Tyler Russell, and Professor Marne Coit of NC State University for a Continuing Legal Education (CLE) seminar. I hope you can join us.
HIA and RE Botanicals filed a legal action against the DEA on Friday regarding the Interim Final Rule it issued on August 21, 2020. We are proud to be part of the legal team.
The issuance of the DEA’s new rule continues a pattern of unwanted and aggressive interference with a lawful industry. This article addresses the DEA’s position on delta-8 THC.
I recently had a wide-ranging discussion about cannabinoids, hemp, and marijuana with Kevin Carrillo of the Cannabinoid Connect podcast. Watch it here.
Despite their similarities, the structural difference between Δ8THC and Δ9THC makes a substantial difference in how they affect our bodies. It also affects their legal status.
Manufacturers of food products containing CBD and other cannabinoid derivatives must submit a Novel Foods application in line with the Novel Foods Regulation in order to sell their products in the European Union.
A physician’s education about cannabis medicine, and her patient’s treatment options, should not depend on their state of residence. Patient access should be based on sound science and physicians should receive comprehensive and uniform education regardless of the state in which they practice.